Generative artificial intelligence promises to revolutionize healthcare, influencing areas like drug development and expediting diagnoses. However, the World Health Organization (WHO) issued a cautionary note on Thursday, emphasizing the need for heightened attention to associated risks.
Exploring AI Large Multi-Modal Models (LMMs) in Healthcare
The WHO has been actively evaluating the potential benefits and risks posed by AI Large Multi-Modal Models (LMMs), a relatively recent development rapidly gaining prominence in the healthcare sector. LMMs represent a form of generative AI capable of utilizing diverse data inputs, including text, images, and video, to generate outputs not restricted to the type of data fed into the algorithm.
According to the Manila Bulletin, LMMs are anticipated to find extensive applications in healthcare, scientific research, public health, and drug development. The organization outlined five key areas where this technology could be deployed: diagnosis, scientific research and drug development, medical and nursing education, clerical tasks, and patient-guided use for investigating symptoms.
Balancing Potential With Recognized Risks
While acknowledging the potential benefits, the WHO cautioned against documented risks associated with LMMs. These risks include the potential for generating false, inaccurate, biased, or incomplete outcomes.
The WHO highlighted the inevitability of errors, misuse, and potential harm to individuals as LMMs gain broader usage in healthcare. To address these concerns, the organization issued recommendations on the ethics and governance of LMMs to guide governments, tech firms, and healthcare providers in safely leveraging this technology.
According to WHO, Chief Scientist Jeremy Farrar emphasized the potential of generative AI technologies to improve healthcare but stressed the crucial need for identifying and fully addressing associated risks. The guidance called for collaborative development involving scientists, engineers, medical professionals, and patients.
Additionally, the WHO underscored the vulnerability of LMMs to cybersecurity risks, emphasizing the necessity for regulatory approval, auditing, and impact assessments in healthcare settings. As generative AI continues to evolve, vigilance and ethical considerations remain paramount for its responsible integration into healthcare practices.
Photo: Scott Graham/Unsplash


Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



